

February 26, 2025

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

To all stakeholders,

(Amendment) Amendment to “PPMX-T003: Selection as FY2026/3 Project Promoting Support
for Drug Discovery Support Program for Orphan drug prior to the Designation by AMED”

Perseus Proteomics Inc. (“the Company”) hereby announces an amendment to “PPMX-T003: Selection as FY2026/3 Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation by AMED” announced today. The amended part is underlined.

1. Before amendment

The research group of Dr. Ai Kotani at Osaka Metropolitan University has discovered that PPMX-T003 has the potential of a therapeutic drug for ANKL.

2. After amendment

The research group of Dr. Ai Kotani at Osaka University has discovered that PPMX-T003 has the potential of a therapeutic drug for ANKL.

END